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Abstract The NLRP3 inflammasome is an intracellular
complex that regulates the release of proinflammatory
cytokines such as interleukin-1β in response to exogenous
pathogens and endogenous danger signals. Evidence from
studies involving human genetics, human ex vivo mono-
nuclear cell responses, and in vivo and in vitro murine
models confirms the importance of the inflammasome and
interleukin-1β in the pathogenesis of several inherited and
complex diseases. The availability of several effective
interleukin-1β targeted therapies has allowed for successful
proof-of-concept studies in several of these disorders.
However, many other diseases are likely to be mediated
by the inflammasome and interleukin-1β, providing addi-
tional targets in the future.
Keywords Inflammasome . Interleukin-1 .
Autoinflammatory . Neutrophil . Biologic therapy . NLRP3 .
Cryopyrin
Introduction
There are two classes of innate immune receptors: Toll-like
receptors (TLRs), located on cell membranes, and
nucleotide-binding oligomerization domain-like receptors
(NLRs) located in the cytoplasm of cells. Both classes of
receptors are programmed to recognize microbial pathogen-
associated molecular patterns (PAMPs), which can stimu-
late secretion of proinflammatory and other cytokines. The
focus of this discussion is on describing diseases that are
confirmed or potentially associated with the unique NLRP3
inflammasome (Fig. 1), which, in addition to stimulation by
PAMPs, can also be stimulated by danger-associated
molecular patterns (DAMPs) to secrete interleukin (IL)-1β
and other IL-1 cytokine family members, such as IL-18.
DAMPs include extracellular adenosine triphosphate, sev-
eral crystals (including uric acid/urate, calcium pyrophos-
phate, silica), and reactive oxygen species. Although
members of the IL-1 cytokine family have significant and
in some cases parallel biological activities, this discussion
focuses on IL-1β secretion because of its known ability to
induce neutrophilic inflammatory responses. The induction
of neutrophilic inflammation by IL-1β has been docu-
mented in the cryopyrinopathies and other inherited auto-
inflammatory diseases. The study of hereditary syndromes
has confirmed that IL-1β can initiate downstream robust
neutrophilic inflammation, which can be reversed and
controlled with IL-1β targeted therapy (TT). Consequently,
several investigators have recognized that targeting IL-1β
may have beneficial effects in the treatment of inflamma-
tory conditions with predominant neutrophilia or neutro-
philia mixed with other inflammatory cellular infiltrates. In
this review, we consider inflammatory disorders in which
IL-1β has been implicated as a pathogenic mediator and in
which IL-1β TT has been used successfully or is being
considered as a therapeutic modality in the future (Table 1).
The NLRP3 Inflammasome
The NLRP3 inflammasome is an intracellular, multiprotein
complex composed of an NLR protein (NLRP3, also
known as cryopyrin or NALP3), at least one adaptor
protein (apoptosis-associated speck protein with a caspase
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activation and recruitment domain [ASC]), and caspase-1
(IL-1β-cleaving enzyme). NLRP3 serves as a protein
complex scaffold, and ASC bridges NRLP3 to caspase-1,
allowing for its activation. Once activated, caspase-1 can
cleave pro-IL-1β to IL-1β, its mature, active, and secre-
table form (Fig. 1). Once IL-1β leaves the cell, it binds to
the IL-1 receptor, resulting in inflammation. Therefore, the
primary role of the inflammasome is to direct inflammation
by controlling unregulated IL-1β release that can be
damaging to the host while allowing for efficient
cytokine-mediated inflammation when the host is in danger.
The NLRP3 inflammasome has been implicated in the host
response to bacteria such as Staphylococcus aureus and
Neisseria gonorrhoeae, viruses such as Vaccinia and
Influenza, fungal products such as hyphae of Candida
albicans, and parasite-associated byproducts such as ma-
larial hemozoin [1]. However, the unique features of
NLRP3 are the response to DAMPs, which indicate cell
death, such as adenosine triphosphate or uric acid, or cell
stress, such as the formation of reactive oxygen species [2•]
and the presence of disease-causing mutations in patients
with cryopyrinopathies [3].
IL-1β Targeted Therapy
Since the discovery and cloning of IL-1β, this critical
proinflammatory mediator implicated in many diseases has
been a focus of the pharmaceutical industry. The first
successful drug in this class was a recombinant form of the
IL-1 receptor antagonist (RA), a natural inhibitor of IL-1β-
mediated inflammation. This drug, known as anakinra, was
originally developed for use in sepsis, but studies in this
severe systemic and often fatal disease were challenging.
Studies of anakinra in rheumatoid arthritis demonstrated
modest efficacy [4], but the clinical response was sufficient
for US Food and Drug Administration approval in 2001.
Inconsistent results, a short half-life requiring daily dosing,
and painful injection site reactions have discouraged
widespread use of this drug. At least three additional IL-
1-targeted drugs with longer half-lives and fewer injection
site reactions have been developed, including a recombi-
nant protein with high affinity for IL-1β, known as IL-1
TRAP, or rilonacept [5], and two humanized monoclonal
antibodies, canakinumab [6] and XOMA 052 (Berkeley,
CA). Rilonacept and canakinumab were studied in cry-
opyrinopathy patients with significant and consistent
responses and were subsequently approved by the US Food
and Drug Administration under its orphan drug program
[7, 8]. Both drugs are also currently being developed for
treatment of gout [9], and XOMA 052 is being developed
for treatment of type 2 diabetes mellitus.
Disorders with IL-1β Involvement with Recognized
Association with the NLRP3 Inflammasome
Conditions Improved with IL-1β TT
Cryopyrinopathies
The cryopyrinopathies are a continuum of inherited
inflammatory disorders of increasing severity, including
familial cold autoinflammatory syndrome, Muckle-Wells
Fig. 1 The inflammasome. The
inflammasome is an intracellular
protein complex consisting of
NRLP3, apoptosis-associated
speck protein with a caspase
activation and recruitment
domain (ASC), and caspase-1.
Pathogen-associated molecular
patterns (PAMPs) or danger-
associated molecular patterns
(DAMPs) activate the inflam-
masome, resulting in activation
of caspase-1 and cleavage of
pro-interleukin (IL)-1β to form
active IL-1β, which leaves the
cell and can then bind to the
IL-1 receptor, resulting in
inflammation. Several IL-1β
targeted therapies have been
developed. mAb—monoclonal
antibody. Figure design by
S. Brydges
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syndrome, and neonatal-onset, multisystem inflammatory
disease [10]. All of these disorders are characterized by
fever, an urticaria-like rash, and joint symptoms resulting in
significant clinical overlap. However, several unique
features distinguish the three cryopyrinopathy phenotypes.
Familial cold autoinflammatory syndrome is associated
with episodes that are often induced by exposure to cold.
Muckle-Wells syndrome is associated with episodes in-
duced by several triggers but also with a progressive
sensorineural hearing loss and a significant risk of
developing type AA amyloidosis. Neonatal-onset, multi-
system inflammatory disease is associated with severe
central nervous system involvement and unique overgrowth
of the distal femur and patella.
In 2001, positional cloning demonstrated that hetero-
zygous mutations in NLRP3 are the cause of most cases
of cryopyrinopathy [3]. These mutations are hypothesized
to be gain of function, resulting in a hyperactive or
constitutively active inflammasome with subsequent sys-
temic IL-1 release resulting in disease-associated symp-
toms [10]. Translational research led to successful trials
and US Food and Drug Administration approval of IL-1β
TT in the cryopyrinopathies, with life-altering results
[7, 8, 11].
Gout
Gout is an inflammatory condition that leads to accumula-
tion of uric acid/urate crystals in acral joints. The formation
of uric acid/urate crystals in acral joints may occur because
these anatomic regions are exposed and affected by low
ambient temperatures, which encourage uric acid/urate
crystallization. Uric acid/urates crystallize at low temper-
atures, as they have a solubility of 4.5 mg/dL at 30°C,
compared with 7.0 mg/dL at 37°C. The concept of
reversing gout crystal-induced inflammation with IL-1β
Table 1 Inflammasome and IL-1β-mediated diseases
Disorders with IL-1β involvement with recognized association with the NLRP3 inflammasome
Inherited conditions successfully treated with IL-1β TT
•Cryopyrinopathies
••Familial cold autoinflammatory syndrome
••Muckle-Wells syndrome
••Neonatal-onset, multisystem inflammatory disorder
Complex diseases successfully treated with IL-1β TT
•Gout
•Type 2 diabetes mellitus
Complex diseases considered for IL-1β TT
•Bleomycin-induced pulmonary neutrophilic disease
•Silicosis and asbestosis
•Contact allergic dermatitis
Disorders with IL-1β involvement with unconfirmed association with the NLRP3 inflammasome
Inherited conditions successfully treated with IL-1β TT
•Familial Mediterranean fever
•Tumor necrosis factor-associated periodic fever
•Hyper IgD syndrome
•Pyogenic arthritis, pyoderma gangrenosum, and acne
•Deficiency of interleukin-1 receptor antagonist
Complex conditions successfully treated with IL-1β TT
•Systemic-onset juvenile idiopathic arthritis
•Adult-onset Still’s disease
•Schnitzler’s syndrome
Conditions considered for IL-1β TT
•UV-induced skin damage
•Chronic neutrophilic respiratory disorders (severe corticosteroid-resistant neutrophilic asthma, chronic obstructive pulmonary disease)
•Sickle cell chest injury
•Hypoxic-ischemic encephalopathy
•Transplantation organ injury
IL interleukin, TT targeted therapy
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TT was based on observations by several investigators who
recognized that uric acid/urate crystals can stimulate
secretion of IL-1β via the NLRP3 inflammasome [12].
Evidence also indicates that uric acid/urate crystals can
stimulate secretion of IL-1β via TLR2 and TLR4. Results
from several studies support IL-1β TT as beneficial in
refractory acute and chronic gout [9].
Type 2 Diabetes Mellitus
Inflammation of pancreatic islets of patients with type 2
diabetes mellitus is associated with IL-1β secretion and
reduction of IL-1RA. High glucose leads to an increase in
IL-1β, impairment of insulin secretion, and apoptosis.
Many studies in animals and humans have demonstrated
that IL-1β TT can reverse this process with improved
glycemia, β-cell function, and reduced markers of inflam-
mation [13, 14]. Recent work has demonstrated that Nlrp3
knockout animals have improved glucose tolerance and
insulin sensitivity, but no studies have shown the inflam-
mation of pancreatic islet cells associated with type 2
diabetes mellitus is reduced in Nlrp3 inflammasome
knockout animals [13, 14].
Conditions with IL-1β Involvement Considered for IL-1β
TT
Bleomycin-Induced Lung Injury
Bleomycin, a commonly used treatment of solid neoplasms,
is associated with the common side effect of early
pulmonary neutrophilic inflammation and later fibrosis.
Gasse et al. [15] studied a murine model and established
that bleomycin effects occur via uric acid/urate formation
and stimulation of the NLRP3 inflammasome, leading to
IL-1β secretion and neutrophilic inflammation. In a
different murine model, IL-1β TT reversed neutrophilic
pulmonary inflammation caused by bleomycin [16]. To
date, use of IL-1β TT to prevent or reverse bleomycin-
induced neutrophilic pulmonary inflammation in humans
has not been reported.
Silicosis and Asbestosis
The chronic histopathology in these occupational-related
disorders is made up of neutrophils, monocytes, and
other inflammatory cells with resultant interstitial fibro-
sis. The chronicity of these disorders is thought to result
from several immunopathologic pathways, including
secretion of IL-1β from silica and asbestos stimulation
of the NLRP3 inflammasome [17]. Based on these
results, there is rationale to treat these conditions with
IL-1β TT.
Contact Hypersensitivity
Exposure to skin sensitizers, such as trinitrochlorobenzene,
causes type IV Gells and Coombs delayed hypersensitivity
reactions. Elegant studies have demonstrated that delayed
reactions of contact hypersensitivity require IL-1β /IL-18
activation by the NLRP3 inflammasome. Knockout mice
for Nlrp3 or other essential components of this inflamma-
some displayed impaired response to trinitrochlorobenzene
[18]. Future use of IL-1β TT may be appropriate to reduce
and/or prevent contact hypersensitivity responses.
Disorders with IL-1β Involvement with Unconfirmed
Association with the NLRP3 Inflammasome
Conditions Improved with IL-1β TT
Familial Mediterranean Fever
Familial Mediterranean fever (FMF) is the most common
inherited recurrent fever disorder. Affected patients experi-
ence 2- to 3-day-long inflammatory episodes characterized
by fever, abdominal pain, and joint symptoms. Rash and
chest pain can also occur during episodes. However, the
most significant morbidity in these patients is systemic AA
amyloidosis that often results in end-stage renal disease.
The standard treatment is maintenance colchicine, which
has been shown to reduce the frequency and severity of
episodes but also significantly reduces the risk of amyloid-
osis [19•]. Most FMF patients have homozygous mutations
in the MEFV gene that codes for the protein pyrin. Pyrin
has some structural similarities to the NLR proteins and
may interact with NLR inflammasomes or form its own
inflammasome, resulting in dysregulated caspase-1 activa-
tion and IL-1β release [19•]. In addition, mononuclear cells
from FMF patients release higher levels of IL-1β [19•]. For
this reason, some FMF patients who do not respond to or
who cannot tolerate colchicine have been treated with IL-
1β TT, with promising results; however, colchicine remains
the treatment of choice in most patients [20].
Tumor Necrosis Factor Receptor-Associated Periodic
Syndrome
This autosomal dominantly inherited recurrent fever disor-
der, originally known as familial Hibernian fever, is
associated with 1- to 3-week-long episodes of fever,
abdominal pain, and joint symptoms that are often
associated with rash and periorbital swelling. As in FMF,
some patients develop AA amyloidosis and kidney disease.
Symptoms usually respond to high-dose corticosteroids
[19•], but the discovery of heterozygous mutations in the
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TNFR1a gene prompted the use of tumor necrosis factor
(TNF)-α TT (etanercept), with good results initially [21].
However, incomplete abrogation of episodes and persistent
chronic inflammation despite proper dosing and evidence
suggesting that TNF-α-mediated inflammation is dependent
on IL-1β provided the rationale for IL-1β TT, with superior
results to TNF-α TT [22, 23].
Hyper IgD Syndrome
Patients with hyper IgD syndrome experience recurrent
episodes of fever, lymphadenopathy, splenomegaly, and
abdominal pain lasting 3–7 days. This autosomal recessive
disorder is caused by homozygous mutations in the gene
(MVK) resulting in decreased mevalonate kinase activity,
with effects on the isoprenoid pathway of cholesterol
biosynthesis [19•]. Mechanisms responsible for inflamma-
tion are believed to be due to the deficiency of isopreny-
lated proteins, which intersect with the IL-1 pathway. In
support of this mechanism, mononuclear cells from hyper
IgD patients release more IL-1β [19•], and patients have
responded to IL-1 TT [24].
Pyogenic Arthritis, Pyoderma Gangrenosum, and Acne
This rare autosomal dominant disease is characterized by
joint inflammation, cutaneous ulcers, and cystic acne.
Neutrophils are the predominant cell involved in tissue
inflammation. Mutations in the proline-serine-threonine
phosphatase interacting protein-1 are responsible for dis-
ease and are believed to affect interactions with the pyrin
protein, resulting in IL-1-mediated inflammation [19•].
Mononuclear cells from patients release increased IL-1β,
and patients have responded to IL-1 TT [25].
Deficiency of IL-1RA
Deficiency of IL-1RA is a rare autosomal recessive disease
presenting with multifocal osteomyelitis, periostitis, and
pustulosis. Mutations in the gene that codes for IL-1RA
result in loss of function and unregulated IL-1 receptor-
mediated inflammation. Therapy with anakinra results in
complete resolution of symptoms [26].
Systemic-Onset Juvenile Idiopathic Arthritis
and Adult-Onset Still’s Disease
Significant amelioration of signs and symptoms of both of
these systemic inflammatory diseases occurs with use of
anakinra. Results from a three-center pediatric rheumatol-
ogy study and others demonstrated a reduction in large joint
inflammation, corticosteroid dosage, acute-phase reactants,
fever, and rashes in systemic-onset juvenile idiopathic
arthritis and systemic inflammation in adult-onset Still’s
disease [27, 28]. The mechanism for IL-1β secretion in this
disorder is unknown, and no studies are available implicat-
ing involvement of the NLRP3 inflammasome.
Schnitzler Syndrome
Schnitzler syndrome is a rare disease characterized by
fever, bone and joint pain, nonpruritic rash often mistaken
for urticaria, and lymphadenopathy. Associated abnormal
laboratory tests include leukocytosis, elevated erythrocyte
sedimentation rate and other acute phase reactants, neutro-
philic infiltration involving skin lesions, and IgM mono-
clonal gammopathy. Striking improvement occurs
following anakinra therapy, suggesting the pathogenesis is
IL-1β mediated [29]. The cause of IL-1β secretion is
currently unknown, and no studies have implicated
involvement of the NLRP3 inflammasome.
Conditions with IL-1β Involvement Considered
for IL-1β TT
The commonality of the following diverse clinical disorders
with evidence of IL-1β secretion and neutrophilic inflam-
mation is the association of ischemia, hypoxia, and
reperfusion with metabolic acidosis and catabolism of
tissues. It has been hypothesized by one of the authors
(Dr. Wanderer) that these pathophysiologic conditions
cause an increase in byproducts (DAMPs) from breakdown
of cellular nucleotides or proteins, which could stimulate
innate receptors such as NLRP3 to cause secretion of IL-
1β, and subsequent neutrophilic inflammation.
Ultraviolet-Induced Skin Damage
There is evidence using in vitro keratinocytes that the
inflammasome can be activated by UVB radiation and
cause IL-1β secretion [30]. The UVB band is similar to
exposure to sunlight, and release of IL-1β may explain the
fever, leukocytosis, and acute-phase responses seen with
severe sunburns.
Chronic Neutrophilic Pulmonary Disorders
Examples include severe corticosteroid-resistant neutro-
philic asthma and chronic obstructive pulmonary disease.
It has been posited that hypoventilation with hypoperfusion
and reoxygenation exhibit similarities to biphasic pathobi-
ology of classic ischemia reperfusion injury. Low pH in
exhaled breath condensates in these disorders provides
evidence for the existence of acidotic milieu in affected
tissues and cells, which in turn can cause DAMPs
formation, IL-1β secretion, and neutrophilic inflammation.
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This ongoing process may explain steroid unresponsiveness
[31]. Efforts are in progress to test this hypothesis by
treating these diseases with IL-1β TT.
Sickle Cell Anemia
Neutrophilic inflammation is prominent in sickle cell
disease and in transgenic sickle cell disease mice
subjected to hypoxia and reperfusion. In addition,
transgenic sickle cell disease mice compared with wild
mice exhibit a heightened proinflammatory state to
microbial molecules, as marked by elevated neutrophil
counts, increased secretion of soluble vascular adhesion
molecules, and increased secretion of proinflammatory
cytokines (IL-1β and TNF-α). A similar observation of
heightened inflammatory responses to microbial infec-
tions is manifested as chest injury in sickle cell disease
patients. There is also evidence of DAMPs formation in
sickle cell disease, as uric acid elevations are frequently
observed and thought to be caused by a combination of
hemolysis and nucleotide breakdown in tissues induced
by ischemia and reperfusion. Ischemia reperfusion is a
consequence of vasoocclusion from sequestration of
sickle erythrocytes, polymerized free sickle hemoglobin,
activated monocytes, neutrophils adherent to activated
endothelial cells, and embolized fat from bone marrow. It
is now known that PAMPs and DAMPs added to normal
monocytes in vitro can cause synergistic secretion of IL-
1β, which could explain the amplified inflammatory
responses in these patients [32]. A trial involving sickle
cell disease mice challenged by hypoxia and treated with
IL-1 TT is in progress.
Hypoxic-Ischemic Encephalopathy
It has been posited that intrapartum hypoxia-ischemia
through stimulation of the NALP3 inflammasome by
DAMPs has a significant role in causing inflammation
associated with hypoxic-ischemic encephalopathy. The
following is presented as evidence for this hypothesis:
1. Metabolic acidosis (pH <7.0 and base deficit) in fetal
umbilical arterial blood samples obtained at delivery is
one of the International Cerebral Palsy Task Force
putative criteria to diagnose an acute intrapartum
hypoxic event sufficient to cause cerebral palsy. This
indicator of metabolic stress could enhance DAMPs
formation;
2. A newborn pig model subjected to sustained hypoxic
injury exhibited a rapid decrease in phosphocreatine/
inorganic phosphorus ratios, pH, and adenosine tri-
phosphate, all metabolic events that could lead to
DAMPs formation. A perinatal hypoxia-ischemia
rodent model (rat) with carotid arterial occlusion
showed progressive decreases in phosphocreatine and
adenosine triphosphate to values of less than 10% of
the control ipsilateral cerebral hemisphere during the
course of hypoxia-ischemia over a 3-hour duration.
They also demonstrated decreased intracellular pH in
areas affected by arterial occlusion.
3. A study of premature infants with elevated uric acid
concentration, noted on the first postnatal day, subse-
quently developed hypoxic-ischemic-induced injury (ie,
intravascular hemorrhage and/or leukomalacia).
4. The observation of elevated IL-1β levels in spinal
fluid samples obtained from hypoxic-ischemic human
newborns as compared with control newborns eva-
luated for possible sepsis/meningitis that was subse-
quently ruled out [33].
To date, there are no known ongoing studies involving
animal studies comparing hypoxic-ischemic stress between
wild type and Nlrp3 knockout mice or in mice with and
without pretreatment using monoclonal IL-1β TT, and there
are no human trials with IL-1β TT to determine if hypoxic-
ischemic encephalopathy can be reduced with this adjunct
therapy.
Organ Ischemia Reperfusion Injury Disorders (Renal,
Myocardial, Central Nervous System, and Transplantation
Organ Injury)
Increased secretion of IL-1β has been observed in many
models of ischemia reperfusion, including models of
transplantation. It also has been demonstrated in animal
models that IL-1β TT can prevent and/or minimize the
neutrophilic inflammation associated with these models.
Although PAMPs can induce IL-1β secretion, in many of
the animal and transplantation models, PAMPS are not
detected, suggesting that other mechanisms may cause
induction of IL-1β secretion. One such paradigm is the
production of DAMPs formation from the pathobiological
effects of ischemia reperfusion injury, which in turn could
stimulate NLRP3 and cause IL-1β secretion with subse-
quent neutrophilic inflammation [32]. There are no known
trials of IL-1β TT in these conditions.
Conclusions
The discovery of NLRP3 as the cause of rare inherited
autoinflammatory disorders has had a major influence on
our understanding of innate immune receptors and cytokine
responses, mechanisms of IL-1β release, IL-1β-mediated
inflammation, the role of IL-1β in many disorders, and IL-
1β TT. The inflammasome and IL-1β now have been
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implicated in the pathogenesis of rare inherited inflamma-
tory diseases and common and more complex disorders,
and IL-1 TT is now being used successfully with a
significant impact on these patients’ lives.
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